| Heart Failure (HF) |
1 |
0.75 |
| Heart |
0 |
0.71 |
| Biologic Therapy |
0 |
0.66 |
| Cardiomyopathy |
0 |
0.64 |
| Transplantation |
0 |
1 |
| Stem Cell Research and Therapy |
0 |
0.57 |
| Heart Transplantation |
0 |
0.54 |
| Organ Transplantation |
0 |
0.41 |
| Allograft |
0 |
0.36 |
| Transplant Center |
0 |
0.32 |
| Immunocompromise |
0 |
0.29 |
| Xenotransplantation |
0 |
0.29 |
| Chronic Kidney Disease |
0 |
0.23 |
| Renal Failure |
0 |
0.23 |
| End-Stage Renal Disease |
0 |
0.22 |
| Maryland |
0 |
0.19 |
| Genomic Medicine |
0 |
0.16 |
| Graft |
0 |
0.13 |
| Hospital |
0 |
0.13 |
| Surgery |
0 |
0.13 |
| Graft Survival |
0 |
0.11 |
| Gene Editing |
0 |
0.1 |
| Genetics |
0 |
0.1 |
| Kidney |
0 |
0.1 |
| Clinical Research |
0 |
0.06 |
| Extracorporeal Membrane Oxygenation (ECMO) |
0 |
0.06 |
| Manipulation |
0 |
0.06 |
| Multiple Organ Dysfunction Syndrome (MODS) |
0 |
0.04 |
| Board Certification |
0 |
0.03 |
| Child |
0 |
0.03 |
| CRISPR |
0 |
0.03 |
| Cyclosporine |
0 |
0.03 |
| Face |
0 |
0.03 |
| Frailty |
0 |
0.03 |
| Immunology |
0 |
0.03 |
| Monoclonal Antibody |
0 |
0.03 |
| Organ Failure |
0 |
0.03 |
| Physiology |
0 |
0.03 |
| Porcine Endogenous Retrovirus (PERV) |
0 |
0.03 |
| T-Lymphocyte |
0 |
0.03 |
| Ventricular Assist Device |
0 |
0.03 |